Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across ...
Adoptive therapy involves growing immune T cells outside the patient's body to enhance their tumor-fighting capacity upon reinfusion. Uveal melanoma typically resists T cell infiltration, but TIL ...
TIL therapy uses a patient's own T cells, expanded in vitro, to target cancer cells, offering a personalized treatment approach. Amtagvi (lifileucel) is the first FDA-approved TIL therapy for advanced ...
Until recently, solid tumors — which make up 90% of cancer diagnoses — had no cell therapy. However, that changed in 2024, when the FDA approved a treatment from Iovance Biotherapeutics for advanced ...
Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results